tiprankstipranks
Revance Therapeutics (RVNC)
NASDAQ:RVNC
Holding RVNC?
Track your performance easily

Revance Therapeutics (RVNC) Ownership - Who Owns Revance Therapeutics?

624 Followers

Revance Therapeutics (RVNC) Ownership Overview

2.00%20.27%29.21%12.18%36.35%
29.21% Other Institutional Investors
12.18% ETFs
36.35% Public Companies and
Individual Investors
The ownership structure of Revance Therapeutics (RVNC) stock is a mix of institutional, retail, and individual investors. Approximately 61.65% of the company’s stock is owned by Institutional Investors, 2.00% is owned by Insiders, and 36.35% is owned by Public Companies and Individual Investors.
The ownership structure of Revance Therapeutics (RVNC) stock is a mix of institutional, retail, and individual investors. Approximately 49.47% of the company’s stock is owned by Institutional Investors, 2.00% is owned by Insiders, and 12.18% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Nov 19, 2024
David Hollander
Cmo & Global Therapeutics Lead
xxxxxxxxxxxxx
$16296
Apr 17, 2024
Erica Jordan
Chief Commercial Officer
xxxxxxxxxxxxx
$9090
Mar 19, 2024
xxxxxxxxxxxxx
$67436
Mar 19, 2024
Dwight Moxie
Clo & Gc
xxxxxxxxxxxxx
$58276

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$220502
Sep 30, 2024
xxxxxxxxxxxxx
$4141376

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
5,336,012Institution5.09%19,263,003
5,320,546Institution5.07%19,207,171
4,429,606Institution4.22%15,990,878
3,263,852Institution3.11%11,782,506
3,153,520Institution3.01%11,384,207
2,158,645Institution2.06%7,792,708
1,428,000Institution1.36%5,155,080
1,163,173Institution1.11%4,199,055
1,136,083Institution1.08%4,101,260
1,106,848Insider1.06%3,995,721

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
4,429,606Institution4.22%15,990,878
3,263,852Institution3.11%11,782,506
3,153,520Institution3.01%11,384,207
2,158,645Institution2.06%7,792,708
1,428,000Institution1.36%5,155,080
1,163,173Institution1.11%4,199,055
1,136,083Institution1.08%4,101,260
1,072,339Institution1.02%3,871,144
605,983Institution0.58%2,187,599
531,535Institution0.51%1,918,841

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,094,072Institution2.95%18,255,025
2,905,634Institution2.77%10,489,339
1,331,123Institution1.27%7,853,626
931,712Institution0.89%3,363,480
474,418Institution0.45%2,799,066
648,708Institution0.62%2,341,836
330,090Institution0.31%1,947,531
263,477Institution0.25%1,849,399
430,242Institution0.41%1,626,315
326,780Institution0.31%1,179,676

FAQ

Who Owns Revance Therapeutics (RVNC)?
According to the latest TipRanks data, approximately 29.21% of the company's stock is held by institutional investors, 2.00% is held by insiders, and 36.35% is held by retail investors.
    What percentage of Revance Therapeutics (RVNC) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 29.21% of Revance Therapeutics (RVNC) stock is held by institutional investors.
      What percentage of Revance Therapeutics (RVNC) stock is held by retail investors?
      According to the latest TipRanks data, approximately 36.35% of Revance Therapeutics (RVNC) stock is held by retail investors.
        Who owns the most shares of Revance Therapeutics (RVNC)?
        Vanguard owns the most shares of Revance Therapeutics (RVNC).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis